Comparison 2. FLUPHENAZINE vs PLACEBO.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early	1	240	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.34, 0.77]
2 Adverse effects: various outcomes	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 drowsiness	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	4.07 [1.92, 8.62]
2.2 restlessness	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.60, 1.34]
2.3 constipation	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	2.26 [1.12, 4.54]
2.4 nausea or upper gastrointestinal distress	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	1.36 [0.33, 5.49]
2.5 dryness of mouth or throat	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	3.46 [1.22, 9.83]
2.6 dizziness, faintness, weakness	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	2.24 [0.74, 6.73]
2.7 muscle rigidity	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	2.98 [1.28, 6.97]
2.8 nasal congestion	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	2.24 [0.74, 6.73]
2.9 facial rigidity	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	2.64 [0.90, 7.77]
2.10 tremor of hands, arms, face	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	2.24 [0.74, 6.73]
2.11 headache	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	1.12 [0.47, 2.64]
2.12 loss of associated movements	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	7.32 [1.75, 30.53]
2.13 akathesis‐restlessness of feet	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	3.52 [1.04, 11.90]